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Abstract
Orphan nuclear receptors have been instrumental in identifying novel signaling pathways and therapeutic targets.
However, identification of ligands for these receptors has often been based on random compound screens or other biased
approaches. As a result, it remains unclear in many cases if the reported ligands are the true endogenous ligands, – i.e., the
ligand that is bound to the receptor in an unperturbed in vivo setting. Technical limitations have limited our ability to
identify ligands based on this rigorous definition. The orphan receptor hepatocyte nuclear factor 4 a (HNF4a) is a key
regulator of many metabolic pathways and linked to several diseases including diabetes, atherosclerosis, hemophilia and
cancer. Here we utilize an affinity isolation/mass-spectrometry (AIMS) approach to demonstrate that HNF4a is selectively
occupied by linoleic acid (LA, C18:2v6) in mammalian cells and in the liver of fed mice. Receptor occupancy is dramatically
reduced in the fasted state and in a receptor carrying a mutation derived from patients with Maturity Onset Diabetes of the
Young 1 (MODY1). Interestingly, however, ligand occupancy does not appear to have a significant effect on HNF4a
transcriptional activity, as evidenced by genome-wide expression profiling in cells derived from human colon. We also use
AIMS to show that LA binding is reversible in intact cells, indicating that HNF4a could be a viable drug target. This study
establishes a general method to identify true endogenous ligands for nuclear receptors (and other lipid binding proteins),
independent of transcriptional function, and to track in vivo receptor occupancy under physiologically relevant conditions.
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Introduction
Nuclear receptors (NRs) are ligand-dependent transcription
factors that regulate the expression of genes involved in virtually all
aspects of physiology and disease [1,2]. The identification of
ligand-receptor pairs began with the pioneering work of Jensen
[3], Edelman [4] and others who injected radioactive ligands into
animals and observed their binding to nuclear receptor proteins.
These experiments had an inherent bias in that the probe ligand
displaced binding of the true endogenous ligand, which could not
be detected in these assays. The validity of the classical steroid
receptor-ligand pairs are now well established, but the limitations
of existing approaches leave open the possibility that additional
ligands may exist for the classical steroid receptors. Indeed, such
speculation was raised for estrogen receptor some time ago, as well
as more recently [5,6], and for intestinal vitamin D receptor that is
activated by an enterohepatic bile acid [7].
The assignment of endogenous ligands to the so-called orphan
nuclear receptors is even more equivocal [2,8]. Typically, orphan
receptors are screened in transcription-based assays against
random compound collections that include natural or synthetic
molecules; in other cases candidate ligands are identified based on
their structure or biological activity [9]. Alternatively, compounds
are added at supra-pharmacologic doses and their metabolic
products are found to be ligands [10]. Most recently, ligands have
been reported based on fortuitous binding to heterologously
produced recombinant proteins [11–17]. Such studies have been
of enormous value and have lead to the identification of many
novel signaling pathways, drugs and therapeutic targets. None-
theless, ligands have been identified for only about half of the 48
human nuclear receptors and the tally in non-human species is
even lower. Furthermore, it remains unclear how many of the
ligands that have been identified are the actual ligands that are
bound to the receptor in vivo. For example, the first orphan
PLoS ONE | www.plosone.org 1 May 2009 | Volume 4 | Issue 5 | e5609receptor-ligand pair to be identified was 9-cis retinoic acid and
RXR [10], yet it appears unlikely that sufficient 9-cis retinoic acid
exists in vivo to serve as a true endogenous ligand [18].
HNF4a (HNF4A, NR2A1) is another orphan receptor whose
endogenous ligand remains unclear [19–21]. HNF4a is essential to
early development and plays critical roles in hepatocyte differen-
tiation [22–24] and in homeostasis of the adult liver, intestine, and
pancreatic beta cells [25–28]. In humans, mutations in the coding
and promoter regions of HNF4a lead to Maturity Onset Diabetes
of the Young 1 (MODY1), a heritable form of type 2 diabetes [29].
Recent crystallographic studies identified a mixture of tightly
bound fatty acids in the ligand binding pocket (LBP) of bacterially
expressed HNF4a and HNF4c [30,31], but it remains unclear
what ligands are bound when the receptor is expressed in its native
physiological environment. There have also been somewhat
controversial reports of fatty acyl Co-enzyme A thioesters as
HNF4a ligands [32,33].
These studies highlight the need to distinguish between ligands
that may bind under non-native conditions and those that are the
true endogenous ligands. The most rigorous definition of a true
endogenous ligand is a compound that binds the LBP in vivo in the
absence of experimental probes or other perturbations. Identifi-
cation of ligands by this definition requires new technical
approaches.
In addition to identification of endogenous ligands for orphan
(and other) nuclear receptors, new experimental tools to identify
ligands are also needed to address the role of ligands in the
evolution of the nuclear receptor superfamily [34–36]. Examina-
tion of HNF4 is also instructive in this regard as it is present in the
earliest metazoan organisms and is one of the most evolutionarily
conserved nuclear receptors [37,38]. Therefore, the question of
whether HNF4 binds an endogenous ligand, the identity of that
ligand and its effect on HNF4 transcriptional activity is of
particular interest and may be relevant to the entire receptor
superfamily. However, these issues cannot be addressed without an
assay that can identify potential ligands in the absence of a pre-
supposed function.
Here we use an affinity isolation/mass spectrometry (AIMS)
approach to identify the endogenous ligand that is bound to
HNF4a in mammalian cells and in mouse liver. The approach is
unbiased in that it does not make any pre-assumptions as to what
the ligand might be or how it might affect HNF4a function. Our
results indicate that the vast majority of HNF4a is bound to a
single essential fatty acid: linoleic acid (LA). Furthermore, our
results show that the binding is reversible, indicating that LA is an
exchangeable ligand. To our knowledge, this represents the first
time an endogenous ligand has been identified by virtue of its
association with a nuclear receptor in animal tissue.
Results
Identification of an endogenous mammalian HNF4a
ligand
To identify an endogenous ligand for HNF4a, we utilized an
affinity isolation/mass-spectrometry (AIMS) approach outlined in
Figure 1A. Wild type (wt) rat HNF4a2 was expressed in
mammalian COS-7 cells and gas chromatography/mass spec-
trometry (GC/MS) was used to analyze the compounds bound to
HNF4a2 immunoprecipitated (IP’d) from nuclear extracts. We
found that HNF4a2 was associated with linoleic acid (LA, 9,12-
octadecadienoic acid, C18:2-D9,12) (Figure 1B, top panel), an
essential dietary polyunsaturated fatty acid not typically found in
E. coli. Quantification of the levels of LA and wt HNF4a2 protein
indicated that 30–100% of the receptor is occupied by LA,
depending on the experiment. Although the presence of trace
amounts of other fatty acids cannot be excluded, the only peak
clearly identified was that of LA. These findings suggest that LA
represents the predominant fatty acid associated with HNF4a in
mammalian cells. Although unlikely, a trivial explanation for these
findings is that LA is not bound to HNF4a within cells, but
becomes associated with the receptor after lysis. To rule out this
possibility, deuterated LA ([
2H]LA) was added to the lysed cells
and AIMS was performed as in Figure 1A. As expected, HNF4a
was found associated with cellular [
1H]LA but not with buffer-
specific [
2H]LA (see Supplementary Figure S1), indicating that the
HNF4aNLA complex forms in cells prior to lysis.
To determine the specificity of LA binding, we asked whether
LA, or other fatty acids, were bound to HNF4a proteins
containing mutations in the LBP. We first mutated a key arginine
residue (R226) that establishes a critical charge-charge interaction
with the carboxylic acid moiety of the fatty acid [30,31]. This
R226M mutant did not bind LA (Figure 1B, middle), indicating
that binding is specific to the LBP. Similarly, a V255M mutation
that is found in patients with MODY1 [39,40] also failed to bind
LA (Figure 1B, bottom). Taken together, these findings demon-
strate that LA specifically binds to the HNF4a LBP within
mammalian cells.
We next examined whether LA could be removed or replaced
from the HNF4a LBP by manipulating the media conditions. In
cells grown in lipid-depleted serum, some LA remained associated
with HNF4a2, suggesting a relatively tight interaction (Figure 1C,
top panel). Nonetheless, addition of exogenous LA to the lipid-
depeleted media resulted in a ,3-fold increase in the amount of
LA bound (peak intensity 2.2610
7 v. 8.6610
6 without LA)
(Figure 1C, middle). Although we could force this increase in LA
binding, we did not observe an increase in binding of a related
fatty acid (palmitoleic acid, PLA, C16:1) provided under similar
conditions (Figure 1C, bottom). These findings further demon-
strate that HNF4a does not effectively associate with other fatty
acids when expressed in mammalian cells.
To further confirm binding specificity, we sought to create an
orthologous receptor-ligand pair that does not bind endogenous
LA. As noted above, the guanidinium group of R226 makes direct
contact with the carboxylic head group of fatty acids (Figure 1D,
left) [31]. We asked whether an artificial receptor-ligand pair could
be established by reversing this charge interaction – i.e., by
converting R226 to a negatively charged glutamate residue
(R226E) whose carboxylate group is predicted by molecular
modeling to interact with the amine moiety of linoleamide (LAA),
a positively charged amide derivative of LA (Figure 1D, right).
Indeed, AIMS analysis verified that R226E bound LAA in cells,
whereas binding to LA could not be detected (Figure 1E). Taken
together, these findings demonstrate the lipid binding specificity of
HNF4a and suggest that LA binds HNF4a via the R226
guanidinium-carboxylate interaction.
HNF4a ligand binding is reversible in mammalian cells
Previous studies suggested that a variety of fatty acids bind in a
non exchangeable fashion to bacterially expressed HNF4a and
HNF4c [30,31]. The inability to exchange with free fatty acids
would exclude the type of ‘‘on/off’’ regulatory switch that is
characteristic of ligand-modulated nuclear receptors. If so, the
fatty acid might serve more like a co-factor than a hormone [41].
However, these conclusions were based on in vitro studies using
HNF4 expressed in bacterial environments where protein folding,
redox state and lipid milieu differ dramatically from the native
mammalian environment. Thus, we utilized the AIMS technique
to determine the ability of bound LA to freely exchange within
Endogenous NR Ligands
PLoS ONE | www.plosone.org 2 May 2009 | Volume 4 | Issue 5 | e5609Figure 1. Identification of linoleic acid (LA) as the endogenous ligand for mammalian-expressed HNF4a2. (A) Affinity isolation/mass-
spectrometry (AIMS): rat HNF4a2 was purified by immunoprecipitation (IP) from crude nuclear extracts of transfected COS-7 cells using an HNF4a
specific antibody (HNF4a Ab). The amount of HNF4a2 protein recovered was determined by immunoblot (IB) analysis and bound ligands bound were
identified by GC/MS. (B) GC/MS chromatograms (10 to 12 min) comparing compounds extracted from IP’d material from mock-transfected (black) to
HNF4a2-transfected (red) (wt and LBP mutants R226M and V255M) COS-7 cells grown in 10% bovine calf serum (Full Serum). Insets: HNF4a IB
showing input (In, 2% of total), material not bound by the Protein A Sepharose (unbound, UB, 2%), and IP’d material (IP, 4%). (C) Same as in (B)
except lipid-depleted serum (Stripped Serum) was used and vehicle (DMSO), linoleic acid (LA, 30 mM) or palmitoleic acid (PLA, 30 mM) were added to
the media as indicated. Arrow, position of LA and PLA peak as determined by standards. (D) Predicted model of HNF4a2 (WT) with bound LA
Endogenous NR Ligands
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[
2H]LA to cycloheximide-treated cells (Figure 2, left). In the
absence of new HNF4a2 synthesis, we found that within 5 hours
more than half the endogenous [
1H]LA that bound to existing
HNF4a2 was replaced with exogenous [
2H]LA. Conversely, off-
rate experiments showed that pre-bound [
2H]LA was replaced
with exogenously added [
1H]LA within a similar time frame
(Figure 2, right). These results indicate that LA is an exchangeable
ligand that binds native HNF4a in a reversible fashion.
The HNF4a ligand binding pocket is unoccupied in the
livers of fasted animals
We next sought to determine what ligands may bind HNF4a in
vivo under relevant physiological conditions. Livers were removed
from young adult male C57BL/6 mice that were either fed a
standard diet (fed), fasted for 24 hrs (24-hr fast), or fasted for
24 hrs followed by refeeding (re-fed). Hepatic HNF4a was then
IP’d from isolated nuclei and quantified by immunoblot (IB)
analysis (Figure 3A and 3B). GC/MS analysis of the isolated
protein demonstrated that HNF4a bound LA in both the fed and
re-fed state but not after a 24-hr fast (Figure 3C). No other fatty
acid was found bound to HNF4a even when dietary LA was
depleted by fasting, further confirming a preference of HNF4a for
LA. Gel shift analysis showed that HNF4a protein from livers of
fasted animals binds DNA well, indicating that the LA-free
HNF4a retains DNA-binding function (Supplementary Figure S2).
The decrease in HNF4a-bound LA was surprising since the total
free fatty acid pool increases in fasting livers [42]. However, LA
did not increase in 24-hr fasted livers; if anything, LA levels
decreased by ,27% in fasted vs. fed or re-fed livers (Figure 3D).
This is consistent with the dietary requirement for LA and may at
least partially explain the decrease in HNF4a occupancy in fasted
mice (Figure 3C). These findings demonstrate that LA is bound to
native HNF4a in vivo, and that binding is a physiological marker of
the fed, but not the fasted, state.
Function of HNF4a ligand binding
For classical receptor-ligand pairs, ligand binding induces a
conformational change that results in co-regulator recruitment and
subsequent transcriptional modulation. Therefore, many previous
attempts at ligand identification for orphan receptors utilized
transcriptional activation and/or coactivator recruitment as the
primary screen. However, unlike AIMS, these approaches are
biased in that they can only identify ligands that induce
transcriptional activity. Nonetheless, once we had identified LA
in AIMS as binding HNF4a, it seemed reasonable to determine
whether LA could transcriptionally activate HNF4a2 in transfect-
ed CV-1 cells exposed to lipid-depleted medium. No positive effect
of LA was observed on full length HNF4a2 with or without
expression of PGC1a (data not shown), a key coactivator that
mediates HNF4a activity in the liver [43]. Since lack of apparent
LA-responsiveness could reflect the high constitutive activity
mediated by the ligand-independent AF-1 domain [44], we next
examined N-terminally deleted (DN) HNF4a2 constructs that lack
the AF-1. LA also had no effect on DN-HNF4a2 in the presence
(Figure 4A) or absence (data not shown) of PGC1a. Similarly,
significant LA-responsiveness was not observed on other well-
characterized HNF4a responsive promoters (ApoB, PEPCK,
Figure 2. Binding of LA to HNF4a2 is exchangeable in mammalian cells. The on- and off-rate of LA binding to rat HNF4a2 in mammalian
cells was determined by incubating COS-7 cells transfected with HNF4a2 wt with [
2H]LA (30 mM) for 1 to 5 hr after (on-rate) or before (off-rate) a 1.5-
hr treatment with cycloheximide (50 mM, CHX). [
1H]LA (open) and [
2H]LA (filled) bound to HNF4a2 was determined as in Figure 1 and graphed as a
percent of the total bound LA normalized to the amount of HNF4a2 protein in the immunoprecipitate. Absolute amounts of LA and HNF4a2 protein
are noted above each bar.
doi:10.1371/journal.pone.0005609.g002
showing the hydrogen bonding between the Arg226 guanidinium group and the LA carboxylate head group (left panel). Right panel, model of
HNF4a R226E mutant bound to linoleamide (LAA) with the carboxylate group of the Glu226 mutant interacting with the LAA NH2 head group. (E)
GC/MS chromatogram comparison and corresponding IB of HNF4a2 WT (red) and R226E mutant (blue) IP’d from COS-7 cells treated with 30 mM LAA.
LA and LAA peaks are indicated.
doi:10.1371/journal.pone.0005609.g001
Endogenous NR Ligands
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for the utility of the AIMS approach since LA cannot be identified
as an HNF4a ligand by commonly used transcriptional screening
strategies.
The apparent lack of LA responsiveness could reflect a
constitutive activity that is inherent to ligand-free HNF4a.T o
explore this possibility, we examined the transcriptional activity of
the DN derivatives of the two non-LA binding HNF4a mutants
(DN-V255M and DN-R226M) identified in Figure 1B. Since both
mutants retained significant constitutive activity in the presence of
PGC1a (Figure 4: V255M, 100% activity; R226M, 63%), we
conclude that unoccupied HNF4a can activate transcription.
Similar experiments with HNF4a R226E and its orthologous
ligand LAA were not interpretable as R226E does not bind DNA
well (data not shown). Nonetheless, the HNF4a mutants that were
tested demonstrate that LA-free HNF4a, which is characteristic of
the fasted state, retains significant transcriptional activity (Figure 4
and data not shown).
Despite the clear ligand-independent transactivation observed
in the transfection assays on select target genes, it remained
possible that ligand binding could modulate HNF4a activity on
other target genes that we did not examine. It has been well
established for other NR-ligand pairs that ligands can have
different effects on different promoters [9,45–47]. Furthermore,
we hypothesized that LA might have a more pronounced effect on
endogenous targets with the appropriate chromatin structure.
Therefore, we used a genome-wide approach to ask whether there
Figure 3. Native hepatic HNF4a binds endogenous LA in fed
but not fasted mice. (A) Design: As in Figure 1A except with livers
from male C57BL/6 mice fed a standard diet (Fed), fasted for 24 hr (24-
hr Fast) or fasted for 24 hr and re-fed for 24 hr (Re-fed). (B) HNF4a from
hepatic nuclei was IP’d in the absence (2Ab) or presence (+Ab) of the
HNF4a-specific antibody and quantified by IB. HNF4a resolves as a
doublet in this gel system. In, 2% of total input; UB, 2% of unbound
material; IP, 2% of IP’d material. (C) GC/MS chromatograms (9 to
11 min) comparing compounds extracted from IP’d material from fed,
fasted and re-fed animals with (red) or without (black) HNF4a Ab.
Arrow, LA peak. (D) Quantification of the amount of LA in the liver of
fed, 24-hr fasted and re-fed mice using GC/MS. Shown are average
Figure 4. HNF4a exhibits ligand-independent transcriptional
activity. Transient transfection into CV-1 cells maintained in stripped
serum with rat HNF4a2 wt and LBP mutants V255M and R226M lacking
the N-terminal AF-1 domain (DN-HNF4a2, DN-V255M, DN-R226M),
reporter ApoA1x4.TK-Luc and co-activator PGC1a in the absence
(Control) and presence of exogenously added LA (30 mM). Shown are
relative light units (RLU) normalized to b-gal activity +/2 SEM. Statistics:
Bonferroni’s multiple comparison post-test: control vs LA, ns for all
constructs; p,0.001 for mock vs. all constructs; ANOVA p,0.0001.
doi:10.1371/journal.pone.0005609.g004
amounts of LA (nmole/mg liver) from 6 mice +/2 SEM per group.
Statistics: two-tailed t-test: fed vs. fasted, p=0.057; fasted vs. re-fed,
p=0.051; fed vs. re-fed, ns; ANOVA p=0.0641.
doi:10.1371/journal.pone.0005609.g003
Endogenous NR Ligands
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exogenously added LA. We first verified by GC/MS that we could
sufficiently deplete tissue culture cells and HNF4a of endogenous
LA by incubating the cells in serum free media for 60 hr
(Supplementary Figure S3). Then we used a recombinant
adenovirus system to ectopically express HNF4a in a human
colon cancer cell line, HCT116, which does not express
endogenous HNF4a protein (Supplementary Figure S4); since
HNF4a is normally expressed in the colon, this cell line should
provide the appropriate environment to examine the effect of
HNF4a on endogenous target genes. The adenovirus system also
allowed for a prolonged incubation in serum free media in order to
maximally deplete the cells of LA, while still being able to express
HNF4a (Supplementary Figure S4).
We performed expression profiling using Affymetrix whole
human genome Gene Chips on infected cells incubated in the
absence or presence of 30 mM LA for 60 hrs. The results show that
whereas the majority of the genes (72%) were not affected by the
addition of LA in the absence of HNF4a (Figure 5, left pie chart),
among the 168 genes that were constitutively activated 3-fold or
more by HNF4a expression, ,73% were down regulated 20% or
more by the addition of LA. Interestingly, only two HNF4a target
genes were up regulated 20% or more by LA (Figure 5) (see
SupplementaryTableS1foralistofHNF4a targetsaffected byLA).
We next examined the effect of LA on several individual HNF4a
target genes by quantitative real time PCR (qRT-PCR) and again
observed a modest decrease in target gene expression, verifying the
array results (Figure 6B). However, we also noticed that there was a
modest but consistent decrease in the amount of HNF4a protein in
the samples containing LA (Figure 6A). Therefore, we normalized
each individual qRT-PCR result to its appropriate HNF4a protein
level and found that the decrease by LA was no longer significant
(Figure 6C). These results confirm that ligand-free HNF4a has
considerable constitutive transactivation activity and that the
presence of LA does not enhance that activity. If anything, the
presence of LA seemed to modestly repress the constitutive activity
of HNF4a, although that effect may be mediated by an alteration in
the HNF4a protein level.
Discussion
Orphan nuclear receptors are central regulators of a wide range
of physiological and pathological events. Over the past ,20 years,
a number of orphan receptors have been ‘‘de-orphanized,’’ yet
some of those ligand assignments may not represent the actual
ligand that is bound to the receptor in vivo – i.e., the true
endogenous ligand (TEL). Identification of synthetic or non-
endogenous ligands remains critical as those compounds serve as
important experimental tools and provide critical mechanistic
insights into the function of nuclear receptors. Nonetheless, a
complete understanding of receptor-regulated networks requires
knowledge of the TELs as well as how the TELs are generated and
what their affect may be on receptor activity. Existing experimen-
tal strategies are not specifically designed to identify TELs and are
often biased by an implicit assumption that the TEL is contained
within a particular compound library or biological extract. Our
work establishes the AIMS approach as a viable strategy to identify
TELs based purely on their association with a receptor in vivo:n o
pre-assumptions are required as to the nature of the ligand. AIMS
is likely to be applicable to virtually all NRs as the only
requirement is an antibody, or other means to selectively isolate
the receptor. Perhaps the only limitation to this approach is the
ability to obtain sufficient amounts of native receptor to ensure
that the cognate ligand is within the detection limits of the assay.
In addition to identifying endogenous ligands, the AIMS
approach has the unique advantage of being a function-
independent assay. Many of the existing screening technologies
are biased by the assumption that the ligand functions as a
transcriptional modulator – this excludes the possibility of
identifying NR ligands that selectively modulate non-genomic
NR functions such as kinase activation, proteasomal degradation
and intracellular trafficking, etc. [48–51]. Indeed, the existence of
some TELs may have been overlooked because they would not
have been detected by transcription- or coactivator-based screens.
HNF4a is a case in point: here we use the AIMS approach to
demonstrate that LA is the endogenous ligand bound to rat, mouse
and human HNF4a (Figures 1,2,3 and S3) and that addition of LA
fails to alter the activation by the receptor (Figures 4,5,6).
HNF4a is transcriptionally active in the absence of ligand
We also show here that during fasting native HNF4a exists in an
LA-free state (Figure 3), and that the ligand-free HNF4a-PGC1a
complex is transcriptionally active (Figure 4). The ligand-
independent transcriptional activity that is characteristic of
HNF4a in the fasted state is consistent with the physiology of
the fasted liver. Indeed, hepatic gluconeogenesis is stimulated by
fasting-induced expression and recruitment of PGC1a to gluco-
Figure 5. Genome-wide expression profiling of HNF4a in the presence and absence of LA. HCT116 cells infected with a tetracycline-
inducible recombinant adenovirus expressing rat HNF4a1 (Adeno.ratHNF4a1.VSV) were incubated for 60 hr in serum free media in the absence
(DMSO) or presence of 30 mM LA. The experiment, consisting of four experimental conditions (2HNF4 2LA, 2HNF4 +LA, +HNF4 2LA, +HNF4 +LA),
was performed in biological triplicate. All samples had doxycycline and the Tet-On virus; samples without HNF4a (2) and with HNF4a (+) differed
only in infection with Adeno.ratHNF4a1.VSV. Pie charts, results of Affymetrix expression profiling. Effect of LA ($20% change) on all genes in the
absence of HNF4a (left); effect of LA ($20% change) on 168 genes up regulated $3-fold by HNF4a (right).
doi:10.1371/journal.pone.0005609.g005
Endogenous NR Ligands
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also consistent with structural studies that show that the position of
the HNF4a AF-2 is altered primarily by binding of co-factor
peptides [52]. Thus, our finding of transcriptional activity for
ligand-free HNF4a is consistent with the known structural and
physiological activities of this receptor.
HNF4-LA, a primitive receptor-ligand pair?
The origin of NRs and their ligands is a hotly debated topic (see
[34] and references therein), and one that can benefit from
experimental approaches such as the AIMS assay. There are
basically two camps, one that proposes that the ancestral NR was
unliganded (e.g., [53]) and the other that proposes that NRs
always had ligands (often referred to as the ligand exploitation
hypothesis) (e.g., [54]). Since HNF4 is one of the few NRs found in
primitive metazoans such as sponge and coral reef [37,38], it could
be viewed as an ancient receptor and possibly even one of the
founders of the superfamily. As such, it is tempting to speculate on
the significance of our findings on the evolution of receptor-ligand
pairs. There is evolutionary logic to the notion that a relatively
Figure 6. Effect of LA on HNF4a protein levels and target gene expression. Experimental design as described in Figure 5. (A) One of five
representative IBs performed on whole cell extracts of adenovirus-infected HCT116 cells (left) and average quantification of all five blots normalized
to Coomassie stain (right). (B,C) qRT-PCR results normalized to cyclophilin A (PPIA) mRNA (B)o rt oPPIA mRNA and HNF4a protein levels (C) of select
HNF4a targets. The average qRT-PCR result from technical triplicates of each biological sample was normalized to the appropriate HNF4a protein
level. Error bars represent standard deviation of the biological plus technical replicates. Statistics: two-tailed t-test, +HNF42LA vs. +HNF4+LA. *,
p,0.05.
doi:10.1371/journal.pone.0005609.g006
Endogenous NR Ligands
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organisms and could thus serve as a primordial ligand [55].
Binding of more complex ligands (e.g., steroids, retinoids, etc.) may
have been a later development associated with more recently
evolved receptor proteins. If that is the case, and if the more
ancient forms of HNF4 also bound LA, then the results presented
here could impact the discussion of the origins of ligand-dependent
transcription. One possibility is that the modern HNF4aNLA pair
accurately reflects the primitive receptor-ligand pair, which would
suggest that ligand binding activity was acquired in advance of the
ability to modulate transcription. It would also suggest that
subsequent receptor-ligand pairs acquired the AF-2-mediated
conformational switch associated with transcriptional activation
later on during evolution. If so, HNF4 could represent a ‘‘missing-
link’’ in the evolutionary pathway from a non ligand-regulated
transcription factor to a transcription factor that can both bind
and respond to ligand. The alternative hypothesis is that ligand
binding and ligand-regulated transcription appeared at the same
time for HNF4 but ligand-regulated transcription was subsequent-
ly lost at some point during the evolution to modern mammalian
HNF4a. Additional studies are clearly required to appropriately
address these important questions; the application of the AIMS
assay to ancient NRs should prove useful in this regard.
Is there a non transcriptional function for the HNF4a
ligand?
It remains possible that the HNF4 ligand used to have, and/or
continues to have, an as yet-to-be determined function that is
distinct from transcriptional modulation. The physiological linkage
of receptor occupancy to the fasting/fed state raises the possibility
that the ligand contributes to a non-genomic mechanism that
affects this physiological transition. Potential non-genomic activ-
ities that have been linked to other nuclear receptors include
kinase activation, proteasomal degradation and intracellular
trafficking, etc. [48–51]. The identification of LA as an
endogenous HNF4a ligand will open up new avenues of research
that explore the potential for LA to modulate non-transcriptional
activities. This demonstrates the power and utility of the AIMS
approach that identifies ligands based on binding rather than
preconceived notions of function.
Resurrection of HNF4a as a drug target?
Previous studies suggested that a wide variety of fatty acids are
associated with bacterially expressed HNF4 [30,31], though LA
was not among these. In retrospect, this is undoubtedly due to the
fact that E. coli do not have LA [56]. Although HNF4aNLA
interactions were not examined in those studies, the authors
mention that the fatty acids they did observe bound to HNF4
could not be removed without denaturing the protein. This in turn
led to the notion that synthetic HNF4a ligands would have little
utility as they would not be able to compete with a non
exchangeable endogenous ligand. Hence, HNF4a, despite its
many links to human disease, was no longer deemed a suitable
drug target. In sharp contrast, we show here that when HNF4a is
expressed in its native environment, it specifically and reversibly
associates with one predominant fatty acid: LA. We also show that
under certain physiological conditions, the LBP of HNF4a is
unoccupied indicating that ligand binding is specifically linked to
physiological status. These findings suggest that HNF4a may
indeed be a tractable target for small molecule drug discovery. The
predicted function of such synthetic ligands, however, will benefit
from an understanding of the functional role of the endogenous
ligand.
Materials and Methods
Ethics Statement
Care and treatment of experimental animals was in accordance
with guidelines from the University of California, Riverside,
Institutional Animal Care and Use Committee (IACUC).
Affinity Isolation/Mass-Spectrometry (AIMS)
Nuclear extracts containing 2–5 mg (40–100 pmoles) of HNF4a
protein (two to three mouse livers or two 150-mm plates of COS-7
cells transfected with rat HNF4a2) were incubated with 30–45 mg
of HNF4a antibody (Ab) (a445, [20]) for 2 hr at 4uC. (See
Supporting Information Materials and Methods S1 for detailed
methods on preparation of nuclear extracts. Experimental
conditions required the use of rat, mouse and human HNF4a
for different experiments. These receptors are very highly
conserved at the sequence and functional levels as discussed in
Supplementary Figure S5.) Protein A Sepharose beads (50 mlo fa
1:1 suspension in PBS) (Pierce) were added and incubated at 4uC
for 4 hr with gentle rocking. The beads were washed three times at
room temperature with 500 ml sterile, filtered PBS by inverting 7–
10 times and pelleting at 10006 g for 10 min. During the last
wash, 2% or 4% of the beads were sampled and HNF4a was
detected by IB analysis with either HNF4a Ab conjugated to HRP
(Peroxidase Labeling Kit, Roche Pharmaceuticals) or HNF4a Ab
followed by TrueBlot HRP-conjugated antibody (eBiosciences).
Both methods avoid detection of the IgG used in the IP. The gas
chromatography and mass spectrometry (GC/MS) protocol was
adapted from Yuan and Forman [57]. Specifically, IP’d material
(protein plus beads) in PBS was heated at 65uC for 30 min. The
beads were pelleted by low speed centrifugation and the
supernatants were filtered and extracted with two to three volumes
of ethyl acetate three times. Organic fractions were dried under N2
gas and derivatized with N,O,-bis (trimethylsilyl) trifluoacetamide
containing 1% trimethylchorosilane (Pierce) at 55uC for 6 hr, and
subsequently analyzed with a ThermoFinnigan Trace DSQ GC/
MS system run in scanning mode over a m/z range of 50–700.
Following data acquisition, total ion spectra from the samples were
compared to known spectra contained in the NIST 98 Library
using the Finnigan Xcalibur software. Gas chromatographic
separation was performed with Phenomenex ZB-5 (5% phenyl-
95% dimethyl-polysiloxane) column (15 or 30 meters, 0.25 mm
ID, film thickness 0.50 mm). At the start of each run, the column
temperature was kept at 50uC for 1 min, increased using a
gradient of 25uC per min up to 300uC, and held at 300uC for an
additional 8 min (15-meter column) or 15 min (30-meter column).
Difference in retention time of LA is due to different column
lengths; standards were run on all columns.
In vivo Exchange Assay
Rat HNF4a2 cDNA (NM_022180) (pMT7.rHNF4a2) was
introduced into COS-7 cells as described in Supporting Informa-
tion. Cells were maintained in DMEM supplemented with 10%
bovine calf serum and penicillin/streptomycin throughout the
experiment. Nuclear extraction, IP, IB and GC/MS analysis of all
samples were performed as described above and in Supporting
Information. On-rate experiment - To halt de novo protein synthesis,
cells were treated with 50 mM cycloheximide (Sigma) 32 hr after
transfection. After 1.5 hr, fresh media containing 30 mM[
2H]LA
and 50 mM cycloheximide was added. After 0, 1, 2, 3, and 5 hr
[
2H]LA treatment, nuclear extracts were prepared, HNF4a2 was
IP’d, and the associated ligand was analyzed by GC/MS and the
amount of HNF4a2 protein recovered was determined by IB
analysis as described above. Off-rate experiment - Approximately
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2H]LA
was added and the cells were incubated at 37uC for 5 hr to allow
for exchange with pre-bound, non-labeled endogenous LA. Cells
were then treated with 50 mM cycloheximide for 1.5 hr. To
remove the [
2H]LA, the media was replaced with fresh media
containing 30 mM non-labeled LA and 50 mM cycloheximide.
Nuclear extracts were prepared after 0, 1, 2, 3 and 5 hr and
analyzed as described above for the on-rate experiments.
Mouse liver extraction for LA measurement
To determine the amount of LA in whole liver tissue of fed,
fasted, and 24 hr fasted animals, mouse liver tissue (n=6 per
condition, ,20 mg per liver) was homogenized in PBS, then
extracted with 1.1 ml of ethyl acetate. PBS containing various
concentrations of an LA standard were extracted simultaneously
and used to establish a standard curve. Heptadecanoic acid
(20 nmole, Sigma) was added to all samples as an internal control
for extraction efficiency.
Identification of candidate LA-responsive HNF4a target
genes
Human colorectal carcinoma HCT116 cells (#CCL-247,
ATCC) maintained in McCoy’s 5A (Hyclone) media supplement-
ed with 10% Tet System Approved fetal bovine serum (Clontech)
and penicillin/streptomycin at 37uC and 5% CO2 were grown to
50–60% confluency at which point the media was changed to
McCoy’s 5A, penicillin/streptomycin plus 0.15% fatty acid-free
BSA (EMD Biosciences) plus vehicle (0.1% DMSO) or 30 mM
linoleic acid (LA) (Sigma). The cells were then immediately co-
infected with 2.5 MOI each of the Adeno-X Tet-On virus
(Clontech) and the recombinant adenovirus expressing VSV-
tagged rat HNF4a1 under Tet control [58]. (HNF4a1 differs from
HNF4a2 by 10 amino acids in the F domain; both activate
transcription well although HNF4a2 is somewhat more responsive
to co-activators than HNF4a1 [59]. The DNA binding domain of
rat and human (and mouse) HNF4a is 100% identical and hence
these species are anticipated to have very similar if not identical
DNA binding specificity (see Supplementary Figure S5). At 12 hr
post infection, 0.5 mg/ml doxycycline (Sigma) was added to induce
expression of HNF4a and the cells were maintained under serum-
free conditions with vehicle or 30 mM LA for an additional 48 hr
(60 hr total in serum-free conditions with vehicle or LA). All cells
received the same amount of doxycycline and Tet-On virus, but
only those cells also infected with the Adeno.ratHNF4a1.VSV
expressed HNF4a protein. RNA isolated from one-half of three
biological replicate plates using the RNeasy Mini kit (Qiagen) was
pooled and hybridized to the GeneChip Human Genome U133
plus 2.0 (Affymetrix) as per the manufacturer’s protocol in the
Genomics Core in the UCR Institute for Integrated Genome
Biology. Each pooled RNA sample was analyzed on two separate
arrays and the results were averaged (8 arrays total for the four
different conditions – +/2LA +/2HNF4). Whole cell extracts
harvested from the other half of the plate [60] were used to verify
HNF4a protein levels by IB analysis.
Analysis of Array Data
All arrays were analyzed using GC Robust Multi-array Average
(GCRMA) background adjustment and quantile normalization on
probe-level data sets with R software (http://www.bioconductor.
org). When comparing two categories (i.e., +/2LA or +/2HNF4)
we included only those probe sets for which at least one treatment
group had 100% Present (P) or Marginal (M) calls (determined by
the MAS5 algorithm), as has been previously described [61].
Quantitative Real-Time PCR
Quantitative real-time PCR (qRT-PCR) analysis was used to
verify the relative expression of select genes, with preference given
to either known HNF4a targets [21], or genes that contained
promoters previously indicated in the literature to bind HNF4a in
human cells [22,62]. Genomic DNA was removed by DNAse I
treatment at 37uC for 1 hr and the RNA was reverse transcribed
using random hexamers and SuperScript III (Invitrogen). The
resulting cDNA was diluted and analyzed using a MyiQ single-
color real-time PCR detection system (Bio-Rad) and SYBR Green.
Gene-specific primers (see Supplementary Table S2) were
validated over four orders of magnitude and analyzed with the
iQ5 Optical System Software (Bio-Rad); primer pairs were
deemed valid if an input log plot amount versus CT generated
an efficiency of 100%610% and a correlation coefficient of
R
2=0.95060.05. Each biological triplicate was analyzed in
technical triplicate. The relative expression level of the genes
was evaluated using the Pfaffl method [63], normalizing to
cyclophilin A (PPIA) expression.
Supporting Information
Supporting Materials and Methods S1 Reagents, plasmids,
ectopic expression of HNF4a proteins in COS-7 cells, preparation
of mouse liver nuclear extracts, immunoblot (IB) analysis, reporter
gene assay, molecular modeling are described in detail.
Found at: doi:10.1371/journal.pone.0005609.s001 (0.09 MB
DOC)
Figure S1 Binding of LA to HNF4a2 occurs within cells.
Deuterated LA was added to nuclear extracts before IP and
subsequent GC/MS. The ratio of [
1H]LA to [
2H]LA shows that
the LA that is bound to HNF4a2 is derived from endogenous
[
1H]LA.
Found at: doi:10.1371/journal.pone.0005609.s002 (0.07 MB
PDF)
Figure S2 HNF4a from fasted mouse liver binds DNA. EMSA
of nuclear extracts from the livers of fed and 24-hr fasted mice
showing that HNF4a from fasted animals binds DNA, indicating
that the apoHNF4a is functional.
Found at: doi:10.1371/journal.pone.0005609.s003 (1.25 MB
PDF)
Figure S3 Validation of experimental system for LA candidate
gene identification I. GC/MS of endogenous HNF4a IP’d from
human tissue culture cells (Hep3B) incubated in media without
serum +/2 LA for 60 hr showing that LA can be depleted from
the cells and HNF4a.
Found at: doi:10.1371/journal.pone.0005609.s004 (0.23 MB
PDF)
Figure S4 Validation of experimental system for LA candidate
gene identification II. IB analysis of extracts from human colon
cancer cells HCT116 infected with recombinant adenovirus
expressing HNF4a showing a lack of expression of endogenous
HNF4a and a robust expression of the recombinant HNF4a.
Found at: doi:10.1371/journal.pone.0005609.s005 (6.90 MB
PDF)
Figure S5 Alignment of human, mouse and rat HNF4a2 amino
acid sequence. Alignment of the amino acid sequence of these
receptors shows the high degree of similarity, especially in the
DBD and LBD, including the residues that contact that the ligand.
Found at: doi:10.1371/journal.pone.0005609.s006 (0.12 MB
PDF)
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(Affymetrix array results).
Found at: doi:10.1371/journal.pone.0005609.s007 (0.08 MB
PDF)
Table S2 Primers used for qRT-PCR to verify HNF4a target
genes.
Found at: doi:10.1371/journal.pone.0005609.s008 (0.06 MB
PDF)
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